Full name
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment
NCT Number
NCT06497504
Geography
US
Non-US
Locations
Argentina, Brazil, Canada, France, Italy, South Africa, Spain, Taiwan, United Kingdom, United States
Primary Endpoints
Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication. At study week 60
Order
4
Disease
Version
Phase
2
Status
Recruiting